<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433834</url>
  </required_header>
  <id_info>
    <org_study_id>PT001101-00</org_study_id>
    <nct_id>NCT02433834</nct_id>
  </id_info>
  <brief_title>Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment,
      Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess
      the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label
      Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent
      Asthma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2015</start_date>
  <completion_date type="Actual">March 26, 2016</completion_date>
  <primary_completion_date type="Actual">March 26, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15</measure>
    <time_frame>From Day 1 to Within 3 hours post dosing on Day 15 in each of 5 treatment periods</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) within 3 hours post-dosing on Day 15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 15</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 on Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-3 on Day 15</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>FEV1 AUC0-3 is the area under the curve for the change from baseline in FEV1 calculated using the trapezoidal rule. All observed data will be used with the trapezoidal rule to calculate AUC. To aid in interpretation, all AUC values will be normalized by dividing the AUC by the time from the first to the last non-missing value (typically 3 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Pre-dose PEFR Over 14 Days</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>Change from baseline in average daily pre-dose peak expiratory flow rate (PEFR) over 14 days Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Post-dose PEFR Over 14 Days</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Rescue Medication Use Over 14 Days</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Control Questionnaire (ACQ-5) on Day 15</measure>
    <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
    <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>GP MDI 28.8 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI (PT001) 28.8 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 14.4 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI (PT001) 14.4 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 7.2 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI (PT001) 7.2 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 3.6 μg per</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI (PT001) 3.6 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 1.9 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GP MDI (PT001) 1.9 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serevent® Diskus® 50 μg per inhalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Serevent® Diskus® 50 μg per inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium MDI</intervention_name>
    <description>GP MDI</description>
    <arm_group_label>GP MDI 28.8 μg</arm_group_label>
    <arm_group_label>GP MDI 14.4 μg</arm_group_label>
    <arm_group_label>GP MDI 7.2 μg</arm_group_label>
    <arm_group_label>GP MDI 3.6 μg per</arm_group_label>
    <arm_group_label>GP MDI 1.9 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serevent Diskus 50 μg</intervention_name>
    <arm_group_label>Serevent® Diskus® 50 μg per inhalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Give their signed written informed consent to participate

          2. Males and females ranging in age between 18 to 70 years, inclusive, before Screening
             (Visit 1a)

          3. A female is eligible to enter and participate in the study if she is of: Non-child
             bearing potential (ie., physiologically incapable of becoming pregnant, including any
             female who is 2 years post-menopausal); or

             Child bearing potential, has a negative serum pregnancy test at Screening (Visit 1a),
             and agrees to 1 of the following acceptable contraceptive methods used consistently
             and correctly (ie., in accordance with the approved product label and the instructions
             of the physician for the duration of the study, from Screening [Visit 1a] until 14
             days after Visit 12):

               -  Complete abstinence from intercourse; or

               -  Implants of levonorgestrel inserted for at least 1 month prior to the study drug
                  administration, but not beyond the third successive year following insertion; or

               -  Injectable progestogen administered for at least 1 month prior to study drug
                  administration and administered for 1 month following study completion; or

               -  Oral contraceptive (combined or progestogen only) administered for at least one
                  monthly cycle prior to study drug administration; or

               -  Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps)
                  plus spermicidal agent (foam/gel/film/cream/suppository); or

               -  An intrauterine device inserted by a qualified physician, with published data
                  showing that the highest expected failure rate is less than 1% per year; or

               -  Estrogenic vaginal ring; or

               -  Percutaneous contraceptive patches

          4. Asthma History: Have a diagnosis of intermittent asthma or mild to moderate persistent
             asthma, diagnosed at least 6 months prior to Screening (Visit 1a)

          5. Reversibility: Diagnosis of asthma confirmed at Screening (Visits 1 and 2) with
             demonstration of reversibility to a bronchodilator defined as an FEV1 increase of at
             least 12% and at least 200 mL, 30 to 60 minutes after the inhalation of 4 puffs of
             salbutamol/albuterol (Ventolin HFA)

          6. Pulmonary Function: Must have a pre-bronchodilator FEV1 ≥60% and ≤90% of predicted
             normal value at Visit 1a/b and Visit 2a/b

          7. Asthma Maintenance Therapy: For those subjects receiving asthma maintenance therapy,
             they must be on a stable dose of ICS or non-ICS therapy (eg., LTRA) for at least 4
             weeks prior to Screening (Visit 1a).

          8. Results of clinical laboratory tests conducted at Screening (Visit 1a) must be
             acceptable to the Investigator.

        Exclusion Criteria:

          1. Life-Threatening Asthma: A subject must not have life-threatening asthma.
             Lifethreatening asthma is defined as a history of significant asthma episode(s)
             requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
             seizures, or asthma related syncopal episode(s) within the 12 months prior to Visit 1a
             (Screening).

          2. Worsening Asthma: A subject must not have experienced a worsening of asthma that
             involved an emergency department visit, hospitalization, or use of oral/parenteral
             corticosteroids within 6 weeks of Screening (Visit 1a).

          3. Seasonal or Exercise-Induced Asthma Alone: Subjects with only seasonal or
             exerciseinduced asthma are excluded from participation.

          4. Concurrent Respiratory Disease: A subject must not have current evidence or diagnosis
             of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic
             bronchitis, emphysema, COPD, or other respiratory abnormalities other than asthma.

          5. Concurrent Conditions/Diseases: A subject with historical or current evidence of any
             clinically significant, or comorbid or uncontrolled condition or disease state that,
             in the opinion of the Investigator, would put the safety of the subject at risk
             through study participation or would confound the interpretation of the results if the
             condition/disease exacerbated during the study.

          6. Smoking History: Current smokers or former smokers who have stopped smoking within 6
             months prior to enrollment or with a &gt;10 pack year history of cigarettes, cigars, or
             pipe smoking. E-cigarettes and inhaled marijuana should be treated in the same manner
             as tobacco products.

          7. Inhaled Anticholinergic Use: Subjects must not have used inhaled anticholinergics for
             at least the 2 weeks prior to Screening (Visit 1a).

          8. Pregnant women or nursing mothers

          9. Respiratory Tract Infection: Subjects who have had a respiratory tract infection
             within 6 weeks prior to Screening (Visit 1a). Subjects who develop a respiratory tract
             infection during the Screening Period must discontinue from the trial, but will be
             permitted to reenroll at a later date (at least 6 weeks after the resolution of the
             respiratory tract infection).

         10. Uncontrolled Hypertension: Subjects who, in the opinion of the Investigator, have
             clinically significant uncontrolled hypertension.

         11. Liver Function: Subjects with abnormal liver function tests defined as aspartate
             aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total
             bilirubin ≥1.5 times the upper limit of normal on repeat testing.

         12. Renal: a. Subjects with symptomatic prostatic hypertrophy that is clinically
             significant in the opinion of the Investigator (if treated and asymptomatic, the
             subject is eligible for enrollment). Subjects with a trans-urethral resection of
             prostate or full resection of the prostate within 6 months prior to Visit 1a are
             excluded from the study.

             b. Subjects with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator. c. Subjects with a calculated
             creatinine clearance ≤30 mL/minute using Chronic Kidney Disease Epidemiology
             Collaboration (CKD-EPI) formula [Levey, 2009] at Visit 1a and on repeat testing prior
             to Visit 3. Note: Subjects with overactive bladder syndrome treated with oral
             anticholinergics that have been on treatment for at least one month are allowed in the
             study.

         13. Glaucoma: Subjects with a diagnosis of angle closure glaucoma will be excluded,
             regardless of whether or not they have been treated. Subjects with a diagnosis of
             glaucoma (non-angle closure), that in the opinion of the Investigator, has not been
             adequately treated will also be excluded. Subjects with previously diagnosed glaucoma
             who have intraocular pressure controlled with medication(s) are eligible. All
             medications approved for control of intraocular pressures are allowed including
             topical ophthalmic non-selective β-blockers such as betaxolol, carteolol, levobunolol,
             metipranolol, or timolol.

         14. Cancer: Subjects who have cancer that has not been in complete remission for at least
             5 years.

             Note: Subjects with squamous cell carcinoma and basal cell carcinoma of the skin that
             have been resected for cure are not considered exclusionary. Subjects with localized
             prostate cancer that in the opinion of the Investigator, has been adequately worked
             up, is clinically controlled, and the subject's participation in the study would not
             represent a safety concern, are eligible.

         15. Drug Allergy: Subjects who have a history of hypersensitivity to lactose, milk
             proteins, or to any component of the MDI or dry powder inhaler (DPI)

         16. Substance Abuse: Subjects with a known or suspected history of alcohol or drug abuse
             within the last 2-year period prior to Screening (Visit 1a).

         17. Cardiac Conditions/Disease: Subjects with documented myocardial infarction within a
             year from the Screening (Visit 1a) are to be excluded. Subjects with a recent history
             of acute coronary syndrome, or who have undergone percutaneous coronary intervention
             or coronary artery bypass graft within 3 months of Screening (Visit 1a) are to be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahid Siddiqui</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Quartz Hill</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Cornelius</city>
        <state>North Carolina</state>
        <zip>28031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Grove City</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Therapeutics Inc.</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomized, Double-Blind, Chronic-Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo MDI and Open-Label Serevent® Diskus® Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma</recruitment_details>
      <pre_assignment_details>Eligible subjects were randomized to 1 of 24 pre-defined treatment sequences. There were 5 treatment periods lasting 14 days with a 7-14 day washout period in between and a follow-up phone call 7-14 days post final dose. By-sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All patients randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 28.8 µg</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 14.4 µg</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 7.2 µg</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 3.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 1.9 µg</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>SAL 50 µg</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211">Subject PT001101-040014 did not complete Period 4 but completed the study. CSR states 210 completed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population is all patients randomized to treatment and used for Participant Flow. Modified ITT (MITT) population, a subset of ITT Population is all subjects treated, with post-treatment efficacy data from at least 2 treatment periods, no major protocol violation precluding the use of data, used for Baseline Characteristics</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All patients randomized</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="222"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) within 3 hours post-dosing on Day 15</description>
        <time_frame>From Day 1 to Within 3 hours post dosing on Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) within 3 hours post-dosing on Day 15</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" spread="0.0181"/>
                    <measurement group_id="O2" value="0.261" spread="0.0141"/>
                    <measurement group_id="O3" value="0.252" spread="0.0142"/>
                    <measurement group_id="O4" value="0.237" spread="0.0176"/>
                    <measurement group_id="O5" value="0.215" spread="0.0184"/>
                    <measurement group_id="O6" value="0.130" spread="0.0154"/>
                    <measurement group_id="O7" value="0.285" spread="0.0156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 15</title>
        <description>Change from baseline in morning pre-dose trough FEV1 on Day 15</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 on Day 15</title>
          <description>Change from baseline in morning pre-dose trough FEV1 on Day 15</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="159"/>
                <count group_id="O7" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.0165"/>
                    <measurement group_id="O2" value="0.047" spread="0.0116"/>
                    <measurement group_id="O3" value="0.042" spread="0.0118"/>
                    <measurement group_id="O4" value="0.012" spread="0.0159"/>
                    <measurement group_id="O5" value="0.018" spread="0.0168"/>
                    <measurement group_id="O6" value="-0.012" spread="0.0133"/>
                    <measurement group_id="O7" value="0.059" spread="0.0135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-3 on Day 15</title>
        <description>FEV1 AUC0-3 is the area under the curve for the change from baseline in FEV1 calculated using the trapezoidal rule. All observed data will be used with the trapezoidal rule to calculate AUC. To aid in interpretation, all AUC values will be normalized by dividing the AUC by the time from the first to the last non-missing value (typically 3 hours).</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-3 on Day 15</title>
          <description>FEV1 AUC0-3 is the area under the curve for the change from baseline in FEV1 calculated using the trapezoidal rule. All observed data will be used with the trapezoidal rule to calculate AUC. To aid in interpretation, all AUC values will be normalized by dividing the AUC by the time from the first to the last non-missing value (typically 3 hours).</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.0170"/>
                    <measurement group_id="O2" value="0.167" spread="0.0131"/>
                    <measurement group_id="O3" value="0.146" spread="0.0133"/>
                    <measurement group_id="O4" value="0.147" spread="0.0165"/>
                    <measurement group_id="O5" value="0.113" spread="0.0173"/>
                    <measurement group_id="O6" value="0.038" spread="0.0144"/>
                    <measurement group_id="O7" value="0.190" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Pre-dose PEFR Over 14 Days</title>
        <description>Change from baseline in average daily pre-dose peak expiratory flow rate (PEFR) over 14 days Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Pre-dose PEFR Over 14 Days</title>
          <description>Change from baseline in average daily pre-dose peak expiratory flow rate (PEFR) over 14 days Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="97"/>
                <count group_id="O6" value="158"/>
                <count group_id="O7" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="4.947"/>
                    <measurement group_id="O2" value="-6.54" spread="4.032"/>
                    <measurement group_id="O3" value="-10.65" spread="4.052"/>
                    <measurement group_id="O4" value="-2.98" spread="4.905"/>
                    <measurement group_id="O5" value="-10.52" spread="5.130"/>
                    <measurement group_id="O6" value="-22.57" spread="4.345"/>
                    <measurement group_id="O7" value="-3.00" spread="4.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Post-dose PEFR Over 14 Days</title>
        <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Post-dose PEFR Over 14 Days</title>
          <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="99"/>
                <count group_id="O6" value="159"/>
                <count group_id="O7" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.53" spread="4.568"/>
                    <measurement group_id="O2" value="-2.86" spread="3.790"/>
                    <measurement group_id="O3" value="-5.38" spread="3.801"/>
                    <measurement group_id="O4" value="3.09" spread="4.530"/>
                    <measurement group_id="O5" value="-5.68" spread="4.680"/>
                    <measurement group_id="O6" value="-21.65" spread="4.041"/>
                    <measurement group_id="O7" value="3.55" spread="4.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Rescue Medication Use Over 14 Days</title>
        <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Rescue Medication Use Over 14 Days</title>
          <description>Daily pre-dose PEFR and daily post-dose PEFR will each be calculated as the average of the AM and PM measurements recorded for a given day. If either the AM or PM assessment is missing, only the single measurement will be used. Analyses of average daily pre-dose PEFR, average daily post-dose PEFR, and rescue Ventolin HFA usage will use the average of the non-missing daily values recorded in the subject diaries over each week and over the last week of treatment within each period.</description>
          <population>Modified Intent-to-Treat (mITT) population was a subset of the Intent-to-Treat (ITT) Population and included all subjects who received treatment, had post-treatment efficacy data from at least two treatment periods, and did not hav e a major protocol violation that would preclude the use of data from these periods.</population>
          <units>Puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="161"/>
                <count group_id="O7" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.132"/>
                    <measurement group_id="O2" value="-0.25" spread="0.105"/>
                    <measurement group_id="O3" value="-0.24" spread="0.105"/>
                    <measurement group_id="O4" value="-0.24" spread="0.131"/>
                    <measurement group_id="O5" value="-0.23" spread="0.136"/>
                    <measurement group_id="O6" value="-0.11" spread="0.114"/>
                    <measurement group_id="O7" value="-0.63" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) on Day 15</title>
        <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
        <time_frame>Day 1-Day 15 in each of 5 treatment periods</time_frame>
        <population>Modified Intent-to-Treat (mITT) population. The modified intent-to-treat (mITT) population included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>GP MDI 3.6 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 1.9 µg</title>
            <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
          </group>
          <group group_id="O6">
            <title>Placebo MDI</title>
            <description>Placebo MDI.</description>
          </group>
          <group group_id="O7">
            <title>SAL 50 µg</title>
            <description>salmeterol 50 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Control Questionnaire (ACQ-5) on Day 15</title>
          <description>The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). The scale is 0-6, where 0=minimum and 6=maximum</description>
          <population>Modified Intent-to-Treat (mITT) population. The modified intent-to-treat (mITT) population included all randomized patients who received at least one dose of study drug. Patients were analyzed according to the treatment they received.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="211"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="160"/>
                <count group_id="O7" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.167" spread="0.0586"/>
                    <measurement group_id="O2" value="-0.173" spread="0.0453"/>
                    <measurement group_id="O3" value="-0.113" spread="0.0455"/>
                    <measurement group_id="O4" value="-0.100" spread="0.0578"/>
                    <measurement group_id="O5" value="-0.205" spread="0.0602"/>
                    <measurement group_id="O6" value="-0.056" spread="0.0501"/>
                    <measurement group_id="O7" value="-0.304" spread="0.0505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from Day 1 through Final Follow up Visit, which is 7-14 days post last study drug dose, unless serious. If serious, they are captured from screening Visit 1 through Final Follow up Visit</time_frame>
      <desc>Safety Population includes all subjects who were randomized to treatment and received at least one dose of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>GP MDI 28.8 µg</title>
          <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 28.8 µg</description>
        </group>
        <group group_id="E2">
          <title>GP MDI 14.4 µg</title>
          <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 14.4 µg</description>
        </group>
        <group group_id="E3">
          <title>GP MDI 7.2 µg</title>
          <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 7.2 µg</description>
        </group>
        <group group_id="E4">
          <title>GP MDI 3.6 µg</title>
          <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 3.6 µg</description>
        </group>
        <group group_id="E5">
          <title>GP MDI 1.9 µg</title>
          <description>Glycopyrronium Metered Dose Inhaler (GP MDI) 1.9 µg</description>
        </group>
        <group group_id="E6">
          <title>Placebo MDI</title>
          <description>Placebo MDI.</description>
        </group>
        <group group_id="E7">
          <title>SAL 50 µg</title>
          <description>salmeterol 50 µg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis, viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="174"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="230"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="228"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="174"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Dorinsky, MD, FCCP</name_or_title>
      <organization>Pearl Therapeutics, Inc.</organization>
      <phone>650-305-2600</phone>
      <email>pdorinsky@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

